van der Lelij, Petra http://orcid.org/0000-0002-7461-9645
Newman, Joseph A
Lieb, Simone
Jude, Julian
Katis, Vittorio
Hoffmann, Thomas
Hinterndorfer, Matthias
Bader, Gerd
Kraut, Norbert
Pearson, Mark A
Peters, Jan-Michael
Zuber, Johannes
Gileadi, Opher
Petronczki, Mark http://orcid.org/0000-0003-0139-5692
Funding for this research was provided by:
European Research Council (GA 693949)
Human Frontier Science Program (RGP0057/2018)
Wellcome (106169/ZZ14/Z)
Innovative Medicines Initiative (115766)
European Community’s Seventh Framework Programme (FP7/2007-2013)
European Research Council (ERC PoC GA 862507)
Austrian Science Fund, FWF (GA SFB F47)
AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada (1097737)
Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda